Inhibition of breast cancer metastasis by targeting critical cytoskeletal components of invadopodia

SCHEME: CORE

CALL: 2016

DOMAIN: BM - Translational Biomedical Research

FIRST NAME: Clément

LAST NAME: Thomas

INDUSTRY PARTNERSHIP / PPP: No

INDUSTRY / PPP PARTNER:

HOST INSTITUTION: LIH

KEYWORDS: Cytoskeleton, breast cancer, cancer, CRP2, Hic-5, invadopodia, invasion, LIM domain, metastasis

START: 2017-09-01

END: 2019-08-31

WEBSITE: https://www.lih.lu

Submitted Abstract

Metastasis is the primary cause of death from cancer. An early and critical step of the metastatic cascade is the acquisition by tumor cells of the ability to remodel the extracellular matrix (ECM) and migrate through the stromal environment and tissue barriers. At the subcellular level, this ability is associated with actin-rich, fingerlike, membrane protrusions termed invadopodia. The primary function of invadopodia is to concentrate and secrete matrix metalloproteinases (MMPs) that degrade the ECM to facilitate tumor cell dissemination and cancer progression. In the METASTALIM project we explore the functional and physical interaction between two cytoskeletal proteins which are specifically up-regulated in triple negative breast cancer cells and critically promote invadopodia formation and activity. Using a combination of cellular and molecular approaches, as well as relevant mouse models, we hope to demonstrate that targeting this axis represent a promising point of intervention to inhibit breast cancer invasion and metastasis.

This site uses cookies. By continuing to use this site, you agree to the use of cookies for analytics purposes. Find out more in our Privacy Statement